Lake Oswego, Ore.-based Biotronik has received the FDA’s premarket approval for its Renamic Neo programmer for implanted cardiac rhythm management devices.

The programmer can be used with devices, such as pacemakers, implantable cardiac monitors and implantable cardioverter-defibrillators.

The battery-powered device features a 12-inch LCD touchscreen display, a built-in analyzer and several connectivity options, the company said.

In addition to its programming functions, Renamic Neo allows clinicians to share the programmer screen with — or grant remote programmer control to — Biotronik’s technical support personnel.